Manipulation Therapy Worsens Osteosarcoma Outcomes

Share this content:

the Cancer Therapy Advisor take:

In a study recently published in PLOS One, researchers found that receiving manipulation therapy (MT) before diagnosis increased metastasis and recurrence and decreased survival rate in patients with osteosarcoma. To evaluate this, they enrolled 325 patients with osteosarcoma. Of 200 cases eligible for inclusion in the analysis, 104 had received MT before diagnosis. Results revealed a significant decrease in 5-year survival rate in the MT group as compared with the non-MT group (52.9% vs. 97.9%; P<0.0001). Although tumor volume did not change, the recurrence rate (28.8%) and lung metastasis rate (38.5%) were higher in the MT group versus the non-MT group (6.25% and 8.3%, respectively). Additionally, the skip lesion rate was up to 11.5% in the MT group compared with none in the non-MT group. Poor overall survival was also noted in the MT group. In a mouse model, the researchers found that MT was associated with migration of cancer cells and that the massage promoted cell proliferation and gene delivery, which potentially accounts for the increased metastasis. Although more studies are necessary, physicians should be cautious when treating patients seeking MT or massage, the researchers concluded.

Body-Based Manipulative Practices: Massage Therapy
Manipulation Therapy Worsens Osteosarcoma Outcomes

Osteosarcoma (OS) patients who suffer manipulation therapy (MT) prior to diagnosis resulted in poor prognosis with increasing metastasis or recurrence rate. The aim of the study is to establish an in vivo model to identify the effects of MT on OS. 


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs